Rain Therapeutics

Share on: 

Rain Therapeutics Inc. is a privately-held biotechnology company developing targeted therapies for patients with cancer. Rain’s lead program is RAIN-32, a small molecule MDM2 inhibitor initially being developed for patients with well-differentiated and de-differentiated liposarcoma, as well as other indications exhibiting MDM2 gene amplification or overexpression.

Newark NJ
United States